Light and the Effect on Metabolic Syndrome and Alzheimer's Disease
Alzheimer Disease, Diabetes Mellitus, Type 2
About this trial
This is an interventional treatment trial for Alzheimer Disease
Eligibility Criteria
Inclusion Criteria:
- Diagnosis of mild to moderate Alzheimer's disease or related dementia,
- type 2 diabetes
- sleep disturbance as determined by a score ≥ 5 on the PSQI
Exclusion Criteria:
- insulin-dependent diabetes,
- urinary incontinence
- obstructing cataracts
- macular degeneration
- blindness
- severe sleep apnea or
- restless leg syndrome (RLS)
Sites / Locations
- Rutgers UniversityRecruiting
- Icahn School of Medicine at Mount SinaiRecruiting
- Icahn School of MedicineRecruiting
Arms of the Study
Arm 1
Arm 2
Experimental
Experimental
Aim 1: Active Intervention then Placebo
Aim 1: Placebo Intervention then Active
Tailored Lighting intervention (TLI). The active TLI will provide high circadian stimulation during the day produced by light sources that provide moderate light levels of spectra that are tuned to the sensitivity of the circadian system. The active lighting intervention will be in place for 8 weeks. Following an 8 week washout period, the participants will see the placebo control intervention for 8 weeks.
The placebo lighting intervention is designed to have no effect on the circadian system. The control intervention will be in place for 8 weeks. Following an 8 week washout period, the participants will see the active tailored lighting intervention for 8 weeks.